Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem Pharmacol ; 49(1): 49-56, 1995 Jan 06.
Article in English | MEDLINE | ID: mdl-7840782

ABSTRACT

6-Methylmercaptopurine ribonucleoside-5'-phosphate (MeSPuRMP), the sole metabolite of 6-methylmercaptopurine ribonucleoside (MeSPuRib), is a strong inhibitor of purine de novo synthesis, inducing depletion of intracellular purine nucleotides and subsequent cell death in several tumor cell lines. In this study prevention of MeSPuRib cytotoxicity by compounds of the purine salvage pathway was studied in Molt F4 human malignant T-lymphoblasts. Adenosine, adenine and inosine were able to prevent depletion of the adenine nucleotide pool when used in combination with 0.5 microM MeSPuRib, but had virtually no effect on depletion of guanine nucleotides. Nevertheless, these three purine compounds were able to reduce the cytotoxic effects induced by MeSPuRib. Addition of guanosine to cells treated with 0.5 microM MeSPuRib normalized the guanine nucleotide pool, but adenine nucleotides remained depleted. Under these conditions, inhibition of cell growth was significantly decreased. With the combination of guanosine and 10 microM MeSPuRib, cytotoxicity was increased compared to 10 microM MeSPuRib alone, associated with a depletion of adenine nucleotides to 9% of untreated cells. Since cell growth and cell viability of Molt F4 cells are less inhibited by MeSPuRib under conditions where adenine nucleotide depletion is prevented by purine compounds (and where the other nucleotides are depleted) we conclude that depletion of adenine nucleotides is an important factor in MeSPuRib cytotoxicity.


Subject(s)
Adenine/pharmacology , Mercaptopurine/analogs & derivatives , Methylthioinosine/antagonists & inhibitors , Methylthioinosine/toxicity , Purine Nucleosides/pharmacology , Ribonucleosides/antagonists & inhibitors , Ribonucleosides/toxicity , Adenosine/pharmacology , Antineoplastic Agents/toxicity , Cell Division/drug effects , Cell Survival/drug effects , Cells, Cultured , Guanosine/pharmacology , Humans , Inosine/pharmacology , Mercaptopurine/antagonists & inhibitors , Mercaptopurine/toxicity , Nucleosides/metabolism , Nucleotides/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , Thioinosine/analogs & derivatives , Thioinosine/toxicity , Thionucleotides/toxicity
2.
Biochem J ; 304 ( Pt 1): 163-8, 1994 Nov 15.
Article in English | MEDLINE | ID: mdl-7998928

ABSTRACT

6-Mercaptopurine (6-MP) and methylmercaptopurine ribonucleoside (Me-MPR) are purine anti-metabolites which are both metabolized to methylthio-IMP (Me-tIMP), a strong inhibitor of purine synthesis de novo. Me-MPR is converted directly into Me-tIMP by adenosine kinase. 6-MP is converted into tIMP, and thereafter it is methylated to Me-tIMP by thiopurine methyltransferase, an S-adenosylmethionine (S-Ado-Met)-dependent conversion. S-Ado-Met is formed from methionine and ATP by methionine adenosyltransferase, and is a universal methyl donor, involved in methylation of several macromolecules, e.g. DNA and RNA. Therefore, depletion of S-Ado-Met could result in an altered methylation state of these macromolecules, thereby affecting their functionality, leading to dysregulation of cellular processes and cytotoxicity. In this study the effects of 6-MP and Me-MPR on S-Ado-Met, S-adenosylhomocysteine (S-Ado-Hcy), homocysteine and methionine concentrations are determined. Both drugs cause a decrease in intracellular S-Ado-Met concentrations and an increase in S-Ado-Hcy and methionine concentrations in Molt F4 human malignant lymphoblasts. The effects of both 6-MP and Me-MPR can be ascribed to a decreased conversion of methionine into S-Ado-Met, due to the ATP depletion induced by the inhibition of purine synthesis de novo by Me-tIMP. Both 6-MP and Me-MPR thus affect the methylation state of the cells, and this may result in dysregulation of cellular processes and may be an additional mechanism of cytotoxicity for 6-MP and Me-MPR.


Subject(s)
Mercaptopurine/pharmacology , S-Adenosylmethionine/biosynthesis , Thionucleosides/pharmacology , Adenosine Triphosphate/biosynthesis , Cell Division/drug effects , Cell Survival/drug effects , Humans , Leukemia-Lymphoma, Adult T-Cell/metabolism , Leukemia-Lymphoma, Adult T-Cell/pathology , Tumor Cells, Cultured
3.
Ann Clin Biochem ; 31 ( Pt 2): 174-80, 1994 Mar.
Article in English | MEDLINE | ID: mdl-7914720

ABSTRACT

The effects of inhibition of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in guanine nucleotide de novo synthesis, on cell growth, cell viability, endogenous nucleotide concentrations and concentrations of extracellular nucleosides and bases were studied in Molt F4 human malignant lymphoblasts. Mycophenolic acid (MPA) was used as a specific inhibitor of the enzyme activity. IMPDH activity was maximally inhibited with 0.5 microM MPA. After a 2 h exposure of the cells to 0.5 microM MPA, guanine nucleotides were depleted to approximately 50% of control values, whereas 5-phosphoribosyl-1-pyrophosphate levels increased to approximately 200%. Under these conditions, cytotoxicity became obvious after 24 h. Depletion of guanine nucleotides and cytotoxicity were prevented by addition of guanosine to MPA treatment. Daily supplements of guanosine were required to prevent MPA cytotoxicity during the entire incubation period of 72 h. We conclude that depletion of guanine nucleotides, induced by treatment with MPA, induces a severe and rapid cytotoxicity in Molt F4 cells.


Subject(s)
IMP Dehydrogenase/antagonists & inhibitors , Mycophenolic Acid/pharmacology , T-Lymphocytes/enzymology , Cell Division/drug effects , Cell Survival/drug effects , Humans , Nucleosides/metabolism , Purine Nucleotides/metabolism , Pyrimidine Nucleotides/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , Tumor Cells, Cultured
4.
Biochem Pharmacol ; 46(3): 547-50, 1993 Aug 03.
Article in English | MEDLINE | ID: mdl-8347177

ABSTRACT

Cytotoxicity of 6-mercaptopurine (6MP) and 6-methylmercaptopurine ribonucleoside (Me-MPR) was studied in Molt F4 human malignant lymphoblasts. Both drugs are converted into methylthioIMP (Me-tIMP), which inhibits purine de novo synthesis. Addition of amidoimidazole carboxamide ribonucleoside (AICAR) circumvented inhibition of purine de novo synthesis, and thus partly prevented 6MP and Me-MPR cytotoxicity. Purine nucleotides, and especially adenine nucleotides, were recovered by addition of AICAR. Under these conditions, Me-tIMP formation decreased. The results of this study indicate that formation of Me-tIMP may be important for 6MP cytotoxicity in Molt F4 cells. These data suggest that depletion of adenine nucleotides is the main cause for Me-tIMP cytotoxicity.


Subject(s)
Aminoimidazole Carboxamide/analogs & derivatives , Mercaptopurine/analogs & derivatives , Mercaptopurine/antagonists & inhibitors , Ribonucleosides/pharmacology , Thioinosine/analogs & derivatives , Thionucleosides/antagonists & inhibitors , Tumor Cells, Cultured/drug effects , Adenine Nucleotides/metabolism , Aminoimidazole Carboxamide/pharmacology , Cell Count , Cell Death/drug effects , Drug Interactions , Guanine Nucleotides/metabolism , Humans , Methylthioinosine/analogs & derivatives , Methylthioinosine/metabolism , Thionucleotides/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...